In the past few years, Chinese pharmaceutical companies have focused on the research and development of new drugs and medical devices, mainly for internal needs. Externally, they are basically conducted through foreign-related hospitals.
Only those drugs that are not painful or itchy, but have a large market size and are not particularly strictly regulated, will be sold in the international market and gain a good reputation and market.
For example, their weight loss pill has become the best-selling weight loss product in the world, directly surpassing all other medical weight loss methods and becoming the veritable best-selling drug in the world.
Compared with drugs that can help men regain their prominence, the price of weight-loss drugs is much higher. In terms of market scale, the global market for weight-loss drugs alone has reached 50 billion yuan, and the global market size of the above drugs is also Only 20 billion yuan.
Similar medicines are very popular around the world. Especially with the changes in diet, environmental pollution, open sex, etc., the demand for such auxiliary medicines is accelerating.
As for Chinese pharmaceutical companies using auxiliary drugs to conquer the world, global pharmaceutical companies have little way to stop them because they cannot come up with products that can compete with them.
Since they cannot compete with Chinese pharmaceutical companies through their own research and development, it is not that they have not tried to use crooked ideas. They even tried to bribe internal personnel of Chinese pharmaceutical companies to obtain specific drug formulas, but they were unsuccessful.
It stands to reason that when these drugs apply for patents, the molecular structure of the drug will be stated. Otherwise, it will be difficult to pass the review of many countries' drug administrations, and it will not be able to be marketed in various countries.
However, although the medicines of Chinese pharmaceutical companies also include Western medicines, most of them are Chinese patent medicines. The ingredients in them are very complex and cannot be explained clearly by simple molecular structures.
Generally, when applying, less important ingredients will be selected as molecular formula descriptions, and the actual effect is often the result of the joint action of many ingredients inside.
When I started applying in this way, I did encounter difficulties from many national drug administration departments, and it took a long time to get it approved, so I simply stopped for a while.
However, with the foreign-related hospitals in our country, the number of patients received from all over the world has reached new highs every year, making the names of Chinese medical companies and Chinese pharmaceutical companies widely spread around the world.
And patients from these countries bring huge medical income to our country every year. It is just a medical problem, and countries have no big solution. After all, the skills are not as good as the people, and there is nothing they can do.
You can't let your domestic patients have good access to medical treatment and stop it. If that happens, they will probably be drowned in saliva, because no one can guarantee that they will be disease-free and disaster-free throughout their lives.
But what makes other countries unhappy is that these patients not only need to pay a large amount of medical expenses, but also need to pay a large amount of transportation and travel expenses, which has brought huge benefits to our country.
These profits could have been kept in China, but this is because Chinese medical companies have not built their own hospitals overseas, and Chinese pharmaceutical companies have not applied for listing of these drugs overseas.
Medical and pharmaceutical technology is so powerful that it can really influence the minds of many people, forcing them to follow their own wishes. As a result, Chinese medical companies and Chinese pharmaceutical companies have great influence around the world.
If it were just ordinary pharmaceutical and medical companies, governments around the world would not pay special attention. After all, almost all diseases have related alternative drugs and solutions, but the effects are different.
However, there is a huge difference between the drugs of Chinese pharmaceutical companies and the drugs of ordinary pharmaceutical companies. They can not only alleviate the pain of patients, but also completely cure the patient's disease. It is not an exaggeration to call it a miracle drug.
In fact, the drug regulatory authorities in many countries very much hope that Chinese pharmaceutical companies can explain the principles and detailed formulas of drugs in detail. Obviously, Chinese pharmaceutical companies will not pay attention to them.
Anyway, they are still making a lot of money by relying on these patients who come to China for medical treatment and cooperating with China's Ping An Insurance Company to promote critical illness insurance around the world, so they don't need to pay attention to them at all.
The drug regulatory authorities of various countries that have suffered a hidden loss in this area have to treat these auxiliary drugs applied for by Chinese pharmaceutical companies with caution, because the application description shows that these drugs are also very miraculous.
However, they still want to use old methods to blackmail Chinese pharmaceutical companies, hoping to obtain relevant technical information about these drugs. If not all, some of them can benefit their domestic pharmaceutical companies a lot.
However, Chinese pharmaceutical companies simply ignored them. After a period of time, if the application was not approved, they planned to withdraw the application and only sell these drugs domestically.
If overseas consumers want to obtain these auxiliary drugs, the price will be very expensive, much more expensive than selling them domestically. After all, the consumer population is small, so the unit price is expensive. They mainly make money.
When Chinese pharmaceutical companies planned to withdraw, the drug regulatory authorities of these countries were surprisingly unanimous and approved it. They only needed to carry out relevant clinical trial regulations.
To be honest, Chinese pharmaceutical companies are the only ones in the world that have such treatment. This is due to their strength. Chinese pharmaceutical companies rely on their own efforts to compete with all pharmaceutical companies in the world, and they still have the absolute upper hand.
If you can't compete head-on, you will resort to intrigues. This is normal. After all, no one wants their company to collapse, especially the pharmaceutical giant that was very prosperous before.
Originally, when the drugs of these pharmaceutical giants were used to treat major diseases, treatment was delayed, and none of the drugs was clean and efficient, resulting in higher overall treatment costs for patients.
The most typical example is tumors. Either surgery will cause additional harm to the patient, or chemotherapy will also cause great harm to the patient.
If it is in the early and middle stages, it can be treated at a huge cost, but even if the patient is cured, his body will not be as good as before, and in the late stage, there is basically no need for treatment.
Unlike Chinese pharmaceutical companies, no matter whether it is morning, afternoon or evening, it only takes a few steps, and in about half a month, the patient can be discharged from the hospital healthy, no different from a normal person.
The important thing about replacement is that the overall cost is much lower than the previous protracted treatment. Even if the round-trip air tickets and travel expenses are included, it will not be much higher.
Therefore, in the field of treatment of major diseases, other countries are simply not competitive. This is why their critical illness insurance sells so well. The number of customers purchasing critical illness insurance worldwide has reached 1.5 billion.
Of course, the remaining people also want to buy critical illness insurance. After all, this has been called a life-saving talisman. As long as they don't die immediately and can be dragged to take a plane to China, it can save their lives. This is not just talk.
Anyway, since the establishment of China Medical Company, as long as anyone enters their hospital alive, there has never been a case of death due to illness. Those who died were all caused by systemic failure as their life span was approaching.
Chinese medical companies, whether overseas or at home, enjoy a reputation that cannot be compared with other medical institutions. They are truly the best medical institutions in the world.
In fact, in the past year, governments of several countries have expressed the hope that Chinese medical companies can go to their countries to open medical institutions, and have expressed that they will provide great convenience.
Because after several years, many governments have figured out that if they block it, it will not cause substantial harm to Chinese medical companies and Chinese pharmaceutical companies. On the contrary, domestic public opinion pressure is increasing.
Those who are able to go to China for medical treatment are those with some financial means. It is difficult for people at the lowest level to get the opportunity to go to China for medical treatment. This has actually caused polarization in medical treatment.
It can be said that people who are able to come to China for treatment will have their lifespan greatly extended. As long as they do not die of natural causes, they can get good treatment here, and the people at the bottom obviously do not have this opportunity.
If things go on like this, serious divisions will occur within these countries, and class struggle will inevitably occur. Zhao Yi can already foresee this situation.
This is why Zhao Yi must implement free medical care for all in the country. Both rich and poor people have the same rights to enjoy similar medical resources, so as to avoid social division.
At most, richer people can enjoy more software environment. Chinese medical companies' hospitals also have single rooms with better environment, but the prices are very expensive, just to make money from those rich people.
These above-average comfortable conditions require additional payment. These fees are collected to subsidize and improve the general medical environment of the hospital, which can be regarded as robbing the rich and giving to the poor.
Rich people are generally willing to be made money by Chinese medical companies, because only in this way can their identity be highlighted. Otherwise, what is the point of making so much money
Governments of various countries suddenly changed their minds and wanted to allow Chinese medical companies to enter their domestic markets. They just did not want our country to make too much money, and at least some of the money could be kept at home.
It's just that the current model is the best for Chinese medical companies and Chinese pharmaceutical companies, because they can make money without infighting, which makes them unwilling to go to other countries to wade into troubled waters.
After being rejected by Chinese medical companies and Chinese pharmaceutical companies, governments of various countries have no temper. After all, the hard power is there, and it is not easy to control it.
Because if the guarantee is not enough, politicians like them will need the services provided by Chinese medical companies and the medical drugs provided by Chinese pharmaceutical companies. Even if they are cruel to themselves, the wealthy people in their country will not agree.
Therefore, they can only pass the review of auxiliary drugs by Chinese pharmaceutical companies, hoping to improve the relationship between their government and Chinese pharmaceutical companies, and at the same time, they are afraid that Chinese pharmaceutical companies will lose their temper.
The current situation is that the auxiliary drugs of Chinese pharmaceutical companies have passed clinical trials around the world, but the formulas and ingredients of their auxiliary drugs have always been a mystery.
Because the auxiliary drugs they applied for are confidential formulas, it is impossible to know these things. Even by analyzing the ingredients, it is very difficult.
These medicines are all made by Zhao Yi. When he provided the formula and related preparation technology, he implemented strict confidentiality measures to ensure that it is difficult to analyze the specific ingredients and proportions through technical means.
Even if they analyze certain ingredients, they still need to go through the process of preparation. Obviously these ingredients are difficult to manufacture through industrial methods.
Because most of these drugs from China Pharmaceutical Company are Chinese herbal medicines from Tianji Agriculture and Animal Husbandry Company, extracted through special methods, and there is no industrialized manufacturing technology at all.
If it really could be manufactured through low-cost industrialization, he would have done it long ago. On the one hand, industrial manufacturing is naturally too difficult, and even the technology he has is very complex.
On the other hand, even if it is industrialized manufacturing, the cost is still very high. It is much more expensive than extracting ingredients from Chinese herbal medicines, and it is not as simple and convenient as directly growing Chinese herbal medicines.
It can be said that so far, no pharmaceutical company has figured out the ingredients of Chinese pharmaceutical companies' drugs. Otherwise, it is estimated that they would have been distributed on a large scale in Asan.
Therefore, starting from the year before last, the auxiliary drugs of Chinese pharmaceutical companies have become larger and larger in the global market. At first, consumers only used them tentatively, but found no problems.
Then they became more courageous, and some people even relied almost entirely on these auxiliary drugs and became heavy dependents, forcing relevant pharmacies to control their use.
No matter what kind of medicine it is, as long as it is overdosed, there will be problems. As mentioned before, drinking too much water can lead to water intoxication, let alone medicines.
In order to protect the health of consumers, all drug stores that act as agents for Chinese pharmaceutical companies are required to use their safe medication systems. Every buyer needs to have their real name registered, but under normal circumstances, this information is kept confidential.
The purpose is to track the usage of various medicines by each consumer. If the frequency of purchases is too high, it may cause certain harm to the consumer's body, they will be refused to purchase. If the pharmacy violates the regulations, their agent qualifications will be cancelled.
Of course, I am excusing myself by doing this. In short, I have taken the measures. If consumers use informal channels to obtain drugs and cause overdose problems, it has nothing to do with Chinese pharmaceutical companies.
Chinese pharmaceutical companies cannot fully guarantee whether other drug chain companies can comply with the regulations. After all, they will not stand by to supervise them all the time, as long as they can avoid getting into trouble.
As for the pharmaceutical chain companies under Shangtong Trading Company, they strictly implement the regulations of China Pharmaceutical Company, because the head office will conduct regular inspections with the market inspectors of China Pharmaceutical Company.
As a brother company, if Shangtong Trading Company seriously damages the interests of China Pharmaceutical Company, it will be difficult to explain it in front of the boss, and it will inevitably be punished.
Moreover, the current Chinese pharmaceutical companies are no longer small businesses. Last year, the annual operating income exceeded 2.5 trillion yuan, although the revenue scale is much worse than that of Shangtong Trading Company.
However, in terms of profit scale, it is not far behind Shangtong Trading Company. If overseas markets are excluded, it still cannot catch up with the profit scale of Chinese pharmaceutical companies.
Domestic market revenue is their largest single market revenue, with revenue reaching 1 trillion yuan. In addition to drugs and medical devices covered by medical insurance, it is also revenue from medical aesthetics and auxiliary drugs.
If the income from medical insurance wants to grow on a large scale, the domestic economy needs to continue to improve. Therefore, the growth rate in this area is limited, and large-scale growth is impossible.
Therefore, the domestic growth areas in the future will still be the field of medical beauty and the sales of auxiliary drugs. They have already seen the signs of this, but it has not yet fully exploded.
Because the domestic people's income has grown rapidly within one or two years. Although it was in a relatively high growth stage before, most people still spent it on improving their material living conditions. Not many people are willing to invest in these things. Fields spend money.
The sales of domestic medical aesthetics and auxiliary drugs are growing rapidly, which also started the year before last, and the growth rate is higher than medical insurance income. In the future, it will even become their main source of income in the country.
Medical insurance funds are available. Even if medical insurance funds are insufficient, Chinese pharmaceutical companies still need to subsidize Chinese medical companies. This time and again is equivalent to limiting the scale of Chinese pharmaceutical companies in making money in this area.
Another source of income is critical illness insurance funds. The scale of global critical illness insurance funds has reached 900 billion US dollars, which is a very high growth compared with before.
The premiums for critical illness insurance vary from high to low, depending on the industry and job the customer is engaged in, as well as their previous and family medical history, in addition to their current physical condition, etc.
Premiums vary in different situations, but on average, the monthly premium per customer is an average of US$50, which is significantly lower than the previously set minimum of US$80.
This is why there are so many people buying critical illness insurance now. US$50 per month is affordable for most people.
Most middle-class families buy critical illness insurance for everyone in their family just in case, and they can afford the cost.
Among the US$900 billion, Chinese pharmaceutical companies account for about 60%, the remaining 35% is Chinese medical companies, and 5% is remuneration from China Ping An Insurance.
The remaining income of less than 500 billion yuan mainly comes from medical aesthetic projects in China and income from overseas auxiliary drugs, of which income from auxiliary drugs accounts for more than 70%.
At present, most of the consumers who come to China for medical aesthetics are wealthy people in the countries where they live, and the number of middle-class people who come is still relatively small. Medical aesthetics is not insured, it is difficult, and the fees are also very expensive.
Chinese medical companies are not particularly anxious about this business, because as people become richer, their high medical costs gradually become less expensive.
Moreover, the foreign-related resources of Chinese medical companies will be given priority to critical illness insurance users, who are very busy themselves. If there are too many medical beauty users, they will be a little overwhelmed.
Of course, this is under the condition that Zhao Yi restricts them from going to sea. If they can go to sea, they can use other people's medical resources to do this work, and the occupation of their own resources will be much smaller.
To be honest, the current Chinese pharmaceutical companies are still doing very well, and Zhao Yi is very satisfied with their work, although this achievement was achieved with his full support.
However, it is not easy to operate such a huge business well, especially when it comes to the pharmaceutical field, which requires more caution and carefulness, which is not comparable to ordinary industries.
However, Zhao Yi put forward some suggestions of his own based on their current business operations, hoping to bring them more income while accelerating the weakening of their competitors.
The first one is to speed up the overseas plan of specific drugs for common diseases. Since governments of various countries have already purchased auxiliary drugs, naturally they have to reciprocate the same, and they need to show their support.
Key drugs will definitely not be exported. After all, they are an important part of critical illness insurance. Without this advantage, the critical illness insurance system is likely to collapse.
But he still doesn't have too many worries about conventional specific medicines. In the past, it was just the governments of various countries that made things difficult, which made it difficult to market them overseas. Later, he simply gave up the application.
Chinese pharmaceutical companies later slowly put this matter behind them and became busy with auxiliary drugs. This time he emphasized this point, on the one hand, in order to further expand business income.
On the other hand, this is a preparation to further attack international giants in the field of drugs for common diseases, thus further weakening their hands and leaving them with even less funds for new drug research and development.
The second is to speed up the export business of medical devices. Previously, Chinese pharmaceutical companies basically did not consider exporting their medical devices, but only provided services to Chinese medical companies.
On the one hand, their equipment is indeed very expensive. Because it is advanced, it is naturally expensive. On the other hand, foreign countries also have certain strengths in this area, so the gap will not be particularly large.
Coupled with the away game and the obstruction of internal protectionism, they were very cautious about this international market. Moreover, at that time, their energy was limited and they did not have so much energy to devote to this area.
Several years have passed, and now the domestic business of Chinese pharmaceutical companies is basically being carried out in an orderly manner, and the foreign business is basically carried out through agency companies, which does not cost them too much energy.
So now is the time to explore this market. No matter what the future holds, we must give it a try and persevere. We cannot stop when we encounter some setbacks.
The third is to allow them to speed up the development of overseas markets for vaccines. The domestic vaccine types are basically complete, and some vaccines are provided by state-owned pharmaceutical research companies. They already have the foundation for these vaccines.
The other part is very difficult. There are currently no good vaccine products, so Chinese pharmaceutical companies have come to fill this gap, so their vaccines do not occupy a high share of the domestic market.
It's not that they can't develop alternative vaccines, but they want to take care of the interests of other domestic pharmaceutical R&D companies and fulfill their previous promise not to get involved in their existing pharmaceutical business in China unless it's particularly bad.
Zhao Yi hopes that they can develop all vaccine products and sell them abroad. If the gap between other domestic companies' vaccines of the same model is too large, Chinese pharmaceutical companies will be allowed to license the technology and let them operate the domestic market.
The purpose of this is not that Chinese pharmaceutical companies must take care of domestic pharmaceutical research and development companies, but that they want to allow domestic people to enjoy the best vaccine products in the world, nothing more. (End of chapter)